Clinical Trials Directory

Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

The primary objective of this study is to determine the influence of insulin resistance on drug metabolism and response in obese subjects. The investigators hypothesize that expression of adiponectin (a hormone secreted by fat tissue), and specific variants in the adiponectin gene can predict the insulin resistance and drug response among obese subjects.

Stanford is now accepting new patients for this trial. Please contact Jerry Ingrande, M.D., M.S. at 650-723-7377 for more information.



  • drug : Propofol and Fentanyl administration

Phase: N/A


Ages Eligible For Study:

18 Years - 70 Years

Inclusion Criteria

- Inclusion criteria include patients of adult age - American Society of Anesthesiologists Class I, II, or III, and undergoing elective surgical procedures requiring general anesthesia - Body mass index greater than 35

External Links

Contact information

Primary Contact:

Jerry Ingrande, M.D., M.S. 650-723-7377

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: